Document is current

Article History

Received: 29 April 2022

Accepted: 1 June 2022

First Online: 15 June 2022

Declarations

:

: Not applicable.

: Not applicable.

: Elizabeth M. Burton (EMB): nothing to disclose. Rodabe N. Amaria (RNA): <i>Research funding and advisory board</i>: Novartis, BMS, Iovance. Tina Cascone (TC): <i>speaker fees/honoraria</i>: The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; <i>advisory role/consulting fees</i>: MedImmune/AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; <i>Institutional research funding</i>: MedImmune/AstraZeneca, Bristol Myers Squibb, and EMD Serono. Myriam Chalabi (MC): MSD, BMS, Roche-Genentech (<i>research funding to the institute</i>). Neil Gross (NG): <i>Research Support, Consulting</i>: Regeneron; Ad-hoc Scientific Advisory Board: Sanofi- Genzyme, Shattuck Labs; <i>Scientific Advisory Board</i>: PDS Biotechnology; <i>Consulting</i>: DragonFly, Intuitive Surgical; <i>Institutional Consulting</i>: Verb Surgical. Elizabeth A. Mittendorf (EAM): <i>Scientific Advisory Board</i>: AstraZeneca, Genomic Health, Merck, Peregrine Pharmaceuticals, Roche/Genentech, Sellas lifesciences, TapImmune; <i>Clinical Trial Support (to institution):</i> AstraZeneca, EMD Serono, Galena Biopharma, Roche/Genentech; <i>Research Support</i>: Glaxo SmithKline; <i>Steering Committees</i>: BMS, Lilly, Roche/Genentech Richard A. Scolyer (RAS): has <i>received fees for professional services</i> from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics and GlaxoSmithKline. <i>Funding:</i> is supported by an NHMRC Practitioner Fellowship (APP1141295). Padmanee Sharma (PS): <i>Consulting or Stock Ownership or Advisory Board</i>: Achelois, Adaptive Biotechnologies, Affini-T, Apricity, BioAtla, BioNTech, Candel Therapeutics, Catalio, Codiak, Dragonfly, Earli, Enable Medicine, Glympse, Hummingbird, ImaginAb, Infinity Pharma, JSL Health, Lava Therapeutics, Lytix, Marker, Oncolytics, PBM Capital, Phenomic AI, Polaris Pharma, Sporos, Time Bioventures, Trained Therapeutix, Two Bear Capital, Venn Biosciences. Paolo A. Ascierto (PAA): <i>Employment or Leadership Position</i>: None; ​ <i>Consultant/Advisory Role</i>: Bristol-Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; <i>Stock Ownership</i>: None; <i>Research Funding</i>: Bristol-Myers Squibb, Roche-Genentech, Pfizer, Sanofi; <i>Expert Testimony</i>: None; <i>Other Remuneration</i>: None.